Humanized antibodies that recognize Verotoxin II and cell line producing same
View Patent ↗The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.
1. A humanized antibody that is a humanized form of a mouse antibody characterized by a light chain variable region of SEQ ID NO:4 and a heavy chain variable region of SEQ ID NO:2, wherein the humanized antibody binds to verotoxin II (VT2).
2. A humanized antibody that competes with the mouse antibody deposited as Accession No. FERM BP-10877 for binding to VT2.
3. A humanized antibody of claim 1 comprising complementarity determining regions from the mouse antibody and heavy and light chain variable region frameworks from the human GF4 antibody heavy (SEQ ID NO: 9) and light (SEQ ID NO:10) chains, provided that at least one position selected from the group consisting of L49, H29, H30, H49 and H98, is occupied by the amino acid present in the equivalent position of the mouse antibody heavy or light chain variable region framework, which humanized antibody binds to verotoxin II.
4. The humanized antibody of claim 3 , provided that each position selected from the group consisting of L49, H29, H30, H49 and H98 is occupied by the amino acid present in the equivalent position of the mouse antibody heavy or light chain variable region framework.
5. The humanized antibody of claim 4 , provided that at least one position selected from the group L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an amino acid present in the equivalent position of a human antibody heavy or light chain consensus sequence.
6. The humanized antibody of claim 5 , provided that each position selected from the group L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an amino acid present in the equivalent position of a human antibody heavy or light chain consensus sequence.
7. The humanized antibody of claim 1 comprising a heavy chain variable region of SEQ ID NO:6 and a light chain variable region of SEQ ID NO:8 provided that one or more positions may be substituted as follows: L49 from K to Y, H29 from F to S, H30 from S to K, H49 from A to R, H98 from R to K, L3 from V to L, L4 from L to M, L19 from A to V, L76 from S to N, L79 from E to Q, L85 from V to L or M, H1 from E to Q, H4 from L to V, H5 from V to L, H79 from L to V, H89 from E to D and H93 from V to M or I.
8. The humanized antibody of claim 1 comprising a heavy chain variable region of SEQ ID NO:6 and a light chain variable region of SEQ ID NO:8.
9. The humanized antibody of claim 1 , comprising a humanized heavy chain having at least 85% identity with the humanized heavy chain of SEQ ID NO:6 and a humanized light chain having at least 85% sequence identity with the humanized light chain of SEQ ID NO:8, provided that at least one position selected from the group consisting of L49, H29, H30, H49 and H98, is occupied by the amino acid present in the equivalent position of the mouse antibody heavy or light chain variable region framework.
10. The humanized antibody of claim 1 or 2 , wherein the antibody comprises two pairs of light/heavy chain dimers, wherein each chain comprises a variable region and a constant region.
11. The humanized antibody of claim 1 or 2 , which is a Fab fragment or a F(ab′) 2 .
12. The humanized antibody of claim 1 or 2 in purified form.
13. The humanized antibody of claim 1 or 2 , which has an IgG 1 immunoglobulin isotype.
14. A method of producing a humanized antibody, comprising culturing a cell line, which encodes heavy and light chain chains of the humanized antibody of claim 1 or 2 , whereby the humanized antibody is expressed; and recovering the humanized antibody expressed by the cell line.
15. The method of claim 14 , further comprising mixing the antibody with a pharmaceutically acceptable carrier to produce a pharmaceutical composition.
16. A pharmaceutical composition comprising the humanized antibody of claim 1 or 2 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising the humanized antibody of claim 8 and a pharmaceutically acceptable carrier.
18. A method of treating a patient suffering or at risk of toxic effects from a verotoxin, comprising administering to the patient an effective dosage of a human or humanized antibody that binds to verotoxin II, wherein the humanized antibody is as defined in claim 1 or claim 2 .
19. The method of claim 18 , wherein the antibody competes with a mouse antibody characterized by a light chain variable region of SEQ ID NO:4 and a heavy chain variable region of SEQ ID NO:2 for binding to VT2.
20. The method of claim 18 , wherein the humanized antibody binds to the B subunit of VT2.
21. The method of claim 18 , wherein the antibody is a humanized antibody comprising a heavy chain variable region of SEQ ID NO:6 and a light chain variable region of SEQ ID NO:8.
22. The method of claim 18 , wherein the patient is infected with verotoxin producing E. coli and the antibody is administered therapeutically.
23. The method of claim 18 , wherein the patient is at risk of infection by verotoxin producing E. coli and the antibody is administered prophylactically.
24. The method of claim 22 , further comprising monitoring the patient for recovery from the toxic effects of VT2.
25. A cell line that produces the antibody of claim 1 or 2 .
26. The humanized antibody of claim 2 that is a humanized form of a mouse immunoglobulin.
27. The humanized antibody of claim 2 that binds the same epitope as the mouse antibody deposited as Accession No. FERM BP-10877.